Chemotherapy for adenocarcinoma of the lung with 5-fluorouracil, cyclophosphamide, and CCNU (FCC)
1979; Wiley; Volume: 44; Issue: 3 Linguagem: Inglês
10.1002/1097-0142(197909)44
ISSN1097-0142
AutoresAgop Y. Bedikian, Richard Staab, Robert B. Livingston, Manuel Valdivieso, Michael A. Burgess, Gerald P. Bodey,
Tópico(s)Lung Cancer Diagnosis and Treatment
ResumoThirty-one adult patients with adenocarcinoma of the lung were treated with FCC chemotherapy consisting of 5-fluorouracil (5-FU), cyclophosphamide, and CCNU every 4 weeks. Thirteen patients received 5-FU orally (POF) at the dose of 400 mg/m2/day in 4 divided daily doses for 5 days, whereas 18 patients received 5-FU at the dose of 800 mg/m2/day for 5 days as a continuous intravenous infusion (CIF). All patients received cyclophosphamide and CCNU orally at doses of 200 mg/m2/day for 4 days and 40 mg/m2/day for 2 days, respectively. The overall response was 22%. Response was greater in patients treated with FCC-CIF (4/14 vs. 1/9; p = 0.6), in patients with limited disease (4/13 vs. 1/10; p = 0.5), and in patients with good performance status, (4/16 vs. 1/7). The overall median survival duration was 9 months. The patients who achieved tumor regression survived significantly longer than patients who had disease stabilization (median, 21 vs. 9 months; p = 0.01), and the latter survived significantly longer than patients who had progressive disease (median, 9 vs. 2.5 months; p = 0.003). There was no significant difference in survival duration in the two FCC-treated groups. Pretreatment extent of disease and performance status did not influence the survival of patients. However, the FCC-CIF-treated group contained a greater number of patients with extensive disease and poor performance status. Further investigations are indicated to evaluate the efficacy of 5-fluorouracil administered by continuous intravenous infusion in combination with cyclophosphamide and CCNU in bronchogenic carcinoma.
Referência(s)